Novo Nordisk and partner dose first patient in clinical heart failure study

After more than a year’s delay, the Danish pharma company rolls out a phase 1/2 clinical study along with Japanese partner Heartseed designed to restore cardiac functions for patients suffering advanced heart failure.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
by marketwire, translated by simon øst vejbæk

Novo Nordisk and partner Tokyo-based Heartseed announce first patient dose in a new cell therapy study.

The clinical study will enroll a total of ten patients and spans for 52 weeks, informs Novo Nordisk in a press release Friday.

Heartseed and Novo Nordisk first publicly announced their global collaboration back in 2021, when Novo Nordisk gained exclusive rights to develop, produce and commercialize HS-001 worldwide except in Japan.

At the time, the clinical phase 1/2 study was slated for the latter half of 2021, meaning the overall delay amounts to slightly more than a year.

HS-001 is an investigational cell therapy consisting of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSC) designed by Heartseed to restore heart muscle and functions in patients with advanced heart failure.

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading